A powerful neuroprotective stack combining mitochondrial ATP synthase modulation, synaptogenesis, and acetylcholine enhancement.
This advanced neuroprotective capsule combines three research compounds with complementary mechanisms targeting neurodegeneration and cognitive enhancement. J147 is a curcumin-derived compound developed at the Salk Institute that has demonstrated remarkable anti-aging effects in animal models, including reversal of cognitive decline in aged mice and protection against Alzheimer’s-like pathology. Dihexa (PNB-0408) is an angiotensin IV analog reported to be approximately 10 million times more potent than BDNF at promoting synaptogenesis in the hippocampus. Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a dipeptide nootropic developed in Russia that has demonstrated cognitive enhancement in human studies and has been used clinically in Russia for cognitive impairment. Together, these three compounds address neuroprotection from the mitochondrial level (J147), the structural level (Dihexa promoting synapse formation), and the neurotransmitter level (Noopept enhancing cholinergic and glutamatergic signaling).
“A powerful neuroprotective stack combining mitochondrial ATP synthase modulation, synaptogenesis, and acetylcholine enhancement.”
J147 was discovered to modulate the alpha subunit of mitochondrial ATP synthase (ATP5A), reducing mitochondrial dysfunction and oxidative stress that accumulate with aging. It also inhibits the enzyme ABAD (amyloid-binding alcohol dehydrogenase) to reduce amyloid toxicity, and activates AMPK to improve cellular energy metabolism. Dihexa promotes synaptogenesis by potentiating HGF/c-Met receptor signaling, activating PI3K/Akt and MAPK/ERK cascades that drive dendritic spine growth and long-term potentiation. Noopept enhances acetylcholine neurotransmission by increasing the sensitivity of nicotinic acetylcholine receptors and upregulating BDNF and NGF expression in the hippocampus and cortex; it also modulates AMPA and NMDA glutamate receptors to enhance synaptic plasticity. The combination provides neuroprotection at the mitochondrial level, structural enhancement through synaptogenesis, and functional improvement through neurotransmitter optimization.
Take with food (J147 is fat-soluble). Morning dosing preferred. Cycle with breaks to prevent tolerance.
Store at room temperature, away from light.
When sourcing J147 + Dihexa + Noopept (Capsule) for research purposes, the following quality benchmarks should be verified before use.
>98% (verified by HPLC)
Must be provided by supplier
<0.1 EU/mg (prevents bacterial contamination)
Manufactured in cGMP-certified facility
Independent lab verification preferred
Store at room temperature, away from light.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.
Early-stage research only. Significant uncertainty about efficacy and safety in humans.
Peptides commonly used alongside J147 + Dihexa + Noopept (Capsule) for synergistic effects.
An angiotensin IV analog reported to be 10 million times more potent than BDNF at promoting synaptogenesis.
An ACTH-derived nootropic peptide that dramatically upregulates BDNF and enhances cognitive performance.
Category
Status
Dose
Frequency
Cycle
Peptides
Protocols
Other Pages
Contact Us Today!
© 2026 Best Health IQ. All rights reserved.
FDA Disclaimer: The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many compounds described on this site are not approved by the FDA for human therapeutic use. Some are available only as compounded preparations or as materials sold for laboratory use, and several are on FDA's Category 2 list for significant safety risks. Nothing on this site constitutes medical advice or a recommendation to use any compound described.
